Aún no tenemos la versión en español de la página que ha solicitado. Puede hacer clic en continuar para ver la página en inglés o cancelar para permanecer en esta página. Pronto estará disponible, gracias por su paciencia.

¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.

CRI featured in USA Today’s End-of-Year Charity Giving Advice

06 de octubre de 2017

Many of our supporters already know that the Cancer Research Institute is among the highest rated cancer charities, but it’s always nice to see that acknowledged by third parties. USA Today’s recent article, “Breast cancer charities: Where to give – and where to avoid” (October 3, 2017), includes CRI among 12 top-rated cancer charities within a subset of organizations doing good work in breast cancer as well as other forms of cancer.

Why is this important to donors? Charity watchdog organizations like the American Institute of Philanthropy, which provided the data cited in the article, rate charity performance based on the services they provide and how much good they are able to do for society with the money they receive from donors. This provides assurance for donors as they consider where to invest their philanthropic dollars. It also helps donors avoid giving to fraudulent, mismanaged, or inefficient organizations.

At CRI we recognize that those who are generous enough to give to us are doing so because they want to make a true difference in the fight against cancer, and to help us bring the hope of more effective treatments to more patients. We strive to keep our overhead costs very low so that we can put the vast majority of donor funds into our programs. In addition to the A rating from Charity Watch, we have a 4-out-of-4-star rating from Charity Navigator, bear the GuideStar Exchange Seal, and we are a member of the Better Business Bureau’s Wise Giving Alliance. Numerous donors have told us that these high ratings were a factor in their selecting us as the recipient of their philanthropic efforts.

To all our supporters, we say “thank you!”, and we will continue to prudently and effectively invest the funds entrusted to us for the benefit of cancer patients. As we approach the “season of giving” at the end of the year, the USA Today article is a good reminder to all of us to do our research and be sure that our money is going where it will do the most good.

Obtenga las últimas actualizaciones sobre inmunoterapia contra el cáncer

*Los resultados de la inmunoterapia pueden variar de un paciente a otro.